Loading
Ovarian Cancer Diagnosis and Treatment / Protein Degradation and Inhibitors · Journal article
BMC Medicine · August 17, 2026
Encouraging direction, but not yet definitive.
This phase Ib/II trial evaluated pamiparib plus surufatinib in 29 platinum-resistant ovarian cancer patients who had progressed on prior PARPi, establishing the RP2D of surufatinib at 250 mg once daily with no DLTs and demonstrating a 6-month PFS rate of 46.7%. The modest objective response rate (8%) and low response proportion, combined with short median follow-up and single-arm design, indicate this is preliminary evidence of potential activity warranting further investigation, with ctDNA showing promise as a predictive biomarker.
Phase Ib/II, open-label, single-arm dose-escalation and expansion trial. Platinum-resistant ovarian cancer patients with documented progression on or after prior PARP inhibitor treatment. Setting and detailed eligibility criteria not specified beyond disease and treatment history.. Intervention: Pamiparib 40 mg twice daily combined with surufatinib starting at 250 mg once daily (adjusted to RP2D 250 mg once daily).. n = 29.
6-month PFS rate was 46.7% (95% CI: 24.4–66.2) Median overall survival was 14.7 months (95% CI: 9.9–NE) Objective response rate was 8% in the efficacy evaluable set
Short median follow-up of 7.3 months with 93% discontinuation rate; durability and long-term outcomes uncertain. Grade 3/4 treatment-related adverse events occurred in 37.9%, with thrombocytopenia (20.7%) and anemia (17.2%) most common
For clinicians treating PARPi-refractory ovarian cancer, this trial suggests the pamiparib–surufatinib combination may offer modest benefit in a difficult-to-treat population, but the low response rate and small sample size mean this is early data. ctDNA monitoring warrants consideration in future trials as a potential response predictor.
Phase Ib/II trial showing modest efficacy (46.7% 6-month PFS) with manageable toxicity in a treatment-refractory population, but limited by small sample size, low objective response rate, and single-arm design without comparator.
As stated by the source record.
Quoted from the source exactly as published.
For clinicians treating PARPi-refractory ovarian cancer, this trial suggests the pamiparib–surufatinib combination may offer modest benefit in a difficult-to-treat population, but the low response rate and small sample size mean this is early data. ctDNA monitoring warrants consideration in future trials as a potential response predictor.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract. Background PARP inhibitors (PARPi) are standard front-line maintenance therapy for advanced ovarian cancer, but the efficacy of PARPi retreatment in later lines remains unclear. This phase Ib/II study evaluated the combination of pamiparib (a PARPi) and surufatinib (a small-molecule tyrosine kinase inhibitor) in platinum-resistant ovarian cancer patients who have progressed on or after prior PARPi treatment. Methods Eligible patients with platinum-resistant ovarian cancer and progression on or after prior PARPi treatment were enrolled. In phase Ib, a 3 + 3 design determined the recommended phase 2 dose (RP2D) of surufatinib in combination with pamiparib (40 mg twice daily). Surufatinib was administered starting at 250 mg once daily, with dose de-escalation if needed. After determining the RP2D, phase II enrollment commenced to assess antitumor activity. The primary endpoints were to establish the RP2D of surufatinib (phase Ib) and the 6-month progression-free survival (PFS) rate (phase II). Tumor tissue sequencing, homologous recombination deficiency (HRD) testing, and dynamic circulating tumor DNA (ctDNA) analysis were also performed. Results A total of 29 patients were enrolled. The RP2D of surufatinib was established at 250 mg once daily, with no dose-limiting toxicities (DLTs). As of the data cut-off (June 20, 2024), the median follow-up was 7.3 (range, 1.0–18.1) months. Two patients remained on treatment, while 27 had discontinued. The 6-month PFS rate was 46.7% (95% CI: 24.4–66.2), and the median overall survival was 14.7 (95% CI: 9.9–NE) months. The objective response rate was 8% in the efficacy evaluable set. Grade 3/4 treatment-related adverse events occurred in 37.9%, with thrombocytopenia (20.7%), and anemia (17.2%) being the most common. No significant difference in PFS was found between BRCA-mutant and wild-type patients, or HRD-positive and HRD-negative tumors. At cycle 7, day 1 (C7D1), ctDNA concentrations were significantly higher in patients who progressed within 6 months (P = 0.05). Patients with ctDNA partial response (CPR) at C3D1 and C7D1 had significantly longer PFS (P = 0.05 and P = 0.01, respectively). Conclusions The combination of pamiparib and surufatinib demonstrated modest yet clinically meaningful antitumor activity with manageable toxicities in platinum-resistant ovarian cancer patients who had progressed on or after prior PARPi treatment. CtDNA may serve as a valuable biomarker for predicting treatment outcomes, warranting further validation in larger studies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.